Showing results 1 to 2 of 2
Title | Author(s) | Issue Date | |
---|---|---|---|
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens Journal:Breast Cancer Research and Treatment | 2021 | ||
Toxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients - The Hong Kong experience Journal:Asia-Pacific Journal of Clinical Oncology | 2009 |